Last 12 months
Inside the activity.
1 purchase rows · 3 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2022 Filed Nov 16, 2022 23:45 UTC |
Meisner LaraGeneral Counsel and Secretary
|
SaleCommon Stock | 8,125 | $22.05 | $179,156.25 |
DisclosureSEC source: 0000899243-22-036044 · doc4.xml · nonDerivative · entry 2 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.04 to $22.845. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.04 to $22.845. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 23:45 UTC |
Meisner LaraGeneral Counsel and Secretary
|
Exercise / conversionCommon Stock | 8,125 | $14.00 | $113,750.00 |
DisclosureSEC source: 0000899243-22-036044 · doc4.xml · nonDerivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:32 UTC |
Fairmount Funds Management LLCDirector · 10% owner · See Remarks
Fairmount Healthcare Fund GP LLCDirector · 10% owner
Fairmount Healthcare Fund II GP LLCDirector · 10% owner
Fairmount Healthcare Fund L.P.Director · 10% owner
Fairmount Healthcare Fund II L.P.Director · 10% owner
|
PurchaseCommon Stock | 425,531 | $23.50 | $9,999,978.50 |
DisclosureSEC source: 0001104659-22-092992 · tm2224209-1_4seq1.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · 10% owner Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 1,363,764 F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 11:30 UTC |
Morris ArleneDirector
|
GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021801 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-08 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 11:30 UTC |
Kiselak TomasDirector
|
GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021803 · doc4.xml · derivative · entry 1 Kiselak Tomas · CIK 0001830177 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-08 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. F2 · ownership.nature: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 11:30 UTC |
Moses Jennifer K.Director
|
GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021804 · doc4.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-08 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 11:30 UTC |
Harwin Peter EvanDirector
|
GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021802 · doc4.xml · derivative · entry 1 Harwin Peter Evan · CIK 0001663607 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-08 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. F2 · ownership.nature: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:29 UTC |
Violin JonathanDirector · Chief Executive Officer
|
SaleCommon Stock | 30,000 | $12.20 | $366,000.00 |
DisclosureSEC source: 0000899243-22-020717 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,905 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.01 to $12.61. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:23 UTC |
Violin JonathanDirector · Chief Executive Officer
|
SaleCommon Stock | 30,000 | $13.04 | $391,200.00 |
DisclosureSEC source: 0000899243-22-016657 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,905 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.69 to $13.75. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:09 UTC |
Violin JonathanDirector · Chief Executive Officer
|
SaleCommon Stock | 3,600 | $18.93 | $68,148.00 |
DisclosureSEC source: 0000899243-22-013858 · doc4.xml · nonDerivative · entry 2 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,905 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.64 to $19.16. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:09 UTC |
Violin JonathanDirector · Chief Executive Officer
|
SaleCommon Stock | 26,400 | $18.92 | $499,488.00 |
DisclosureSEC source: 0000899243-22-013858 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,505 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.34 to $19.43. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:48 UTC |
Violin JonathanDirector · Chief Executive Officer
|
SaleCommon Stock | 11,106 | $17.36 | $192,800.16 |
DisclosureSEC source: 0000899243-22-009096 · doc4.xml · nonDerivative · entry 2 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,905 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.05 to $18.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:48 UTC |
Violin JonathanDirector · Chief Executive Officer
|
SaleCommon Stock | 18,894 | $17.82 | $336,691.08 |
DisclosureSEC source: 0000899243-22-009096 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,011 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.62 to $18.30. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 03, 2022 Filed Feb 3, 2022 23:11 UTC |
Violin JonathanDirector · Chief Executive Officer
|
SaleCommon Stock | 909 | $19.16 | $17,416.44 |
DisclosureSEC source: 0000899243-22-004665 · doc4.xml · nonDerivative · entry 3 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,905 F3 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.04 to $19.66. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 23:12 UTC |
Meisner LaraGeneral Counsel and Secretary
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-22-004666 · doc4.xml · derivative · entry 1 Meisner Lara · CIK 0001883986 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 18:15 UTC |
Humer KristianCFO and CBO
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-22-004673 · doc4.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 23:13 UTC |
Katz BarrettChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-22-004669 · doc4.xml · derivative · entry 1 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 23:11 UTC |
Violin JonathanDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-22-004665 · doc4.xml · derivative · entry 4 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2032-02-02 F4 · derivative.exercise_date: The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 23:11 UTC |
Violin JonathanDirector · Chief Executive Officer
|
SaleCommon Stock | 12,340 | $18.47 | $227,919.80 |
DisclosureSEC source: 0000899243-22-004665 · doc4.xml · nonDerivative · entry 2 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,814 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.32 to $19.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 23:11 UTC |
Violin JonathanDirector · Chief Executive Officer
|
SaleCommon Stock | 16,751 | $19.55 | $327,482.05 |
DisclosureSEC source: 0000899243-22-004665 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,154 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.90 to $20.23. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 16:16 UTC |
Humer KristianCFO and CBO
|
GrantStock Option (Right to Buy) · Derivative | 121,371 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000899243-22-000130 · doc4.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,371 Underlying: Common Stock · 121,371 shares Expires 2031-12-31 F1 · derivative.exercise_date: The option vests 25% on July 26, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 23:08 UTC |
Violin JonathanDirector · See Remarks
|
ConversionSeries A Non-Voting Convertible Preferred Stock · Derivative | 9,413 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047801 · doc4.xml · derivative · entry 2 Violin Jonathan · CIK 0001730615 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 627,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 66.67 shares of Common Stock, subject to certain limitations. F1 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 66.67 shares of Common Stock, subject to certain limitations. F1 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 66.67 shares of Common Stock, subject to certain limitations. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 23:08 UTC |
Violin JonathanDirector · See Remarks
|
ConversionCommon Stock | 627,564 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047801 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2021 Filed Sep 28, 2021 19:46 UTC |
FHMLSP, L.P.10% owner
FHMLSP, L.L.C.10% owner
|
PurchaseCommon Stock | 200,000 | $11.00 | $2,200,000.00 |
DisclosureSEC source: 0001209191-21-058002 · doc4.xml · nonDerivative · entry 1 Frazier Life Sciences Public Fund, L.P. · CIK 0001863769 · 10% owner FHMLSP, L.P. · CIK 0001879466 · 10% owner FHMLSP, L.L.C. · CIK 0001879465 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,505,200 F1 · balance_after: These shares are held directly by Frazier Life Sciences Public Fund L.P. The general partner of Frazier Life Sciences Public Fund L.P. is FHMLSP, L.P. and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. and FHMLSP, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by Frazier Life Sciences Public Fund L.P., except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 09:30 UTC |
Fairmount Funds Management LLCDirector · 10% owner
Fairmount Healthcare Fund GP LLCDirector · See Remarks
Fairmount Healthcare Fund II GP LLCDirector · See Remarks
Fairmount Healthcare Fund L.P.Director · See Remarks
Fairmount Healthcare Fund II L.P.Director · See Remarks
|
PurchaseCommon Stock | 909,000 | $11.00 | $9,999,000.00 |
DisclosureSEC source: 0000899243-21-037255 · doc4.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 938,233 F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 17:02 UTC |
Humer KristianCFO and CBO
|
GrantStock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $17.09 | $0.00 |
DisclosureSEC source: 0000899243-21-030131 · doc4.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2031-07-26 F1 · derivative.exercise_date: The option vests 25% on July 26, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 20:24 UTC |
Moses Jennifer K.Director
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0000899243-21-028495 · doc4.xml · derivative · entry 1 Moses Jennifer K. · CIK 0001706667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-07-14 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
| June 03, 2021 Filed Jun 16, 2021 22:27 UTC |
Morris ArleneDirector
|
GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000899243-21-024221 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-03 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 3, 2022 or (ii) the Issuer's 2022 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document |
| June 03, 2021 Filed Jun 16, 2021 22:34 UTC |
Kiselak TomasDirector
|
GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000899243-21-024230 · doc4.xml · derivative · entry 1 Kiselak Tomas · CIK 0001830177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-03 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 3, 2022 or (ii) the Issuer's 2022 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document |
| June 03, 2021 Filed Jun 16, 2021 22:26 UTC |
Harwin Peter EvanDirector
|
GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000899243-21-024220 · doc4.xml · derivative · entry 1 Harwin Peter Evan · CIK 0001663607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-03 F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) June 3, 2022 or (ii) the Issuer's 2022 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 22:38 UTC |
Morris ArleneDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000899243-21-005204 · doc4.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 17:41 UTC |
TURNER JOSEPH LDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000899243-21-005209 · doc4.xml · derivative · entry 1 TURNER JOSEPH L · CIK 0001266129 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 22:40 UTC |
Hatfield Jeffrey S.Director
|
GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000899243-21-005208 · doc4.xml · derivative · entry 1 Hatfield Jeffrey S. · CIK 0001609879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 22:40 UTC |
Harwin Peter EvanDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000899243-21-005207 · doc4.xml · derivative · entry 1 Harwin Peter Evan · CIK 0001663607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 22:40 UTC |
Kiselak TomasDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000899243-21-005206 · doc4.xml · derivative · entry 1 Kiselak Tomas · CIK 0001830177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
| January 18, 2021 Filed Jan 19, 2021 20:04 UTC |
Rauch Lee M.See Remarks
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-21-002402 · doc4.xml · derivative · entry 1 Rauch Lee M. · CIK 0001815345 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-17 F1 · derivative.exercise_date: The option vests in equal monthly installments over the following 6 months, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 20:55 UTC |
Leverone Jason A.Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 311,785 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-21-002488 · doc4.xml · derivative · entry 1 Leverone Jason A. · CIK 0001692747 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,785 Underlying: Common Stock · 311,785 shares Expires 2031-01-17 F1 · derivative.exercise_date: The option vests in equal monthly installments over the following 4 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 20:48 UTC |
Violin JonathanDirector · CEO and President
|
GrantEmployee Stock Option (right to buy) · Derivative | 800,075 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-21-002484 · doc4.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,075 Underlying: Common Stock · 800,075 shares Expires 2031-01-17 F1 · derivative.exercise_date: The option vests in equal monthly installments over the following 4 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 18, 2021 Filed Jan 22, 2021 00:33 UTC |
Katz BarrettChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 356,000 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-21-002770 · doc4.xml · derivative · entry 1 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,000 Underlying: Common Stock · 356,000 shares Expires 2031-01-17 F1 · derivative.exercise_date: The option vests 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 23:23 UTC |
Logos Global Master Fund LP10% owner
|
PurchaseCommon Stock | 126,667 | $14.84 | $1,879,598.95 |
DisclosureSEC source: 0001567619-20-019923 · doc1.xml · nonDerivative · entry 3 Logos Global Master Fund LP · CIK 0001831371 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 F2 · shares: After giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F2 · price: After giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F2 · balance_after: After giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. Read SEC document |
| November 09, 2020 Filed Nov 16, 2020 23:23 UTC |
Logos Global Master Fund LP10% owner
|
PurchaseCommon Stock | 100,000 | $1.16 | $116,410.00 |
DisclosureSEC source: 0001567619-20-019923 · doc1.xml · nonDerivative · entry 2 Logos Global Master Fund LP · CIK 0001831371 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,350,000 F1 · shares: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F1 · price: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F1 · balance_after: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. Read SEC document |
| November 09, 2020 Filed Nov 16, 2020 23:23 UTC |
Logos Global Master Fund LP10% owner
|
PurchaseCommon Stock | 250,000 | $1.10 | $274,475.00 |
DisclosureSEC source: 0001567619-20-019923 · doc1.xml · nonDerivative · entry 1 Logos Global Master Fund LP · CIK 0001831371 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250,000 F1 · shares: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F1 · price: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. F1 · balance_after: Before giving effect to a 1-for-15 reverse stock split that occurred on November 12, 2020. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 11:53 UTC |
Fairmount Funds Management LLCDirector · See Remarks
Fairmount Healthcare Fund GP LLCDirector · See Remarks
Fairmount Healthcare Fund II GP LLCDirector · See Remarks
Fairmount Healthcare Fund L.P.Director · See Remarks
Fairmount Healthcare Fund II L.P.Director · See Remarks
|
PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative | 28,843 | $465.96 | $13,439,684.28 |
DisclosureSEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 111,192 Underlying: Common Stock · 28,483,000 shares Expires not disclosed F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 11:53 UTC |
Fairmount Funds Management LLCDirector · See Remarks
Fairmount Healthcare Fund GP LLCDirector · See Remarks
Fairmount Healthcare Fund II GP LLCDirector · See Remarks
Fairmount Healthcare Fund L.P.Director · See Remarks
Fairmount Healthcare Fund II L.P.Director · See Remarks
|
PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative | 5,494 | $465.96 | $2,559,984.24 |
DisclosureSEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 21,999 Underlying: Common Stock · 5,494,000 shares Expires not disclosed F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund LP ("Fund I"). They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC |
Fairmount Funds Management LLCDirector · See Remarks
Fairmount Healthcare Fund GP LLCDirector · See Remarks
Fairmount Healthcare Fund II GP LLCDirector · See Remarks
Fairmount Healthcare Fund L.P.Director · See Remarks
Fairmount Healthcare Fund II L.P.Director · See Remarks
|
OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 82,349 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 82,349 Underlying: Common Stock · 82,349,000 shares Expires not disclosed F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC |
Fairmount Funds Management LLCDirector · See Remarks
Fairmount Healthcare Fund GP LLCDirector · See Remarks
Fairmount Healthcare Fund II GP LLCDirector · See Remarks
Fairmount Healthcare Fund L.P.Director · See Remarks
Fairmount Healthcare Fund II L.P.Director · See Remarks
|
OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 16,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 16,505 Underlying: Common Stock · 16,505,000 shares Expires not disclosed F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC |
Fairmount Funds Management LLCDirector · See Remarks
Fairmount Healthcare Fund GP LLCDirector · See Remarks
Fairmount Healthcare Fund II GP LLCDirector · See Remarks
Fairmount Healthcare Fund L.P.Director · See Remarks
Fairmount Healthcare Fund II L.P.Director · See Remarks
|
OtherCommon Stock | 438,502 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 438,502 F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC |
Fairmount Funds Management LLCDirector · See Remarks
Fairmount Healthcare Fund GP LLCDirector · See Remarks
Fairmount Healthcare Fund II GP LLCDirector · See Remarks
Fairmount Healthcare Fund L.P.Director · See Remarks
Fairmount Healthcare Fund II L.P.Director · See Remarks
|
OtherCommon Stock | 87,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 87,891 F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 21:19 UTC |
Harwin Peter EvanDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0000899243-20-029702 · doc4.xml · derivative · entry 1 Harwin Peter Evan · CIK 0001663607 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-10-26 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 21:16 UTC |
Kiselak TomasDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0000899243-20-029699 · doc4.xml · derivative · entry 1 Kiselak Tomas · CIK 0001830177 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-10-26 F1 · derivative.exercise_date: The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.